High-grade B-cell Lymphoma with Myc and Bcl2 or Bcl6 Rearrangements

• CLINICAL_TRIALS research · 2026-04-22
  Clinical Trial Update: Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating the effectiveness of ViPOR in relapsed/refractory aggressive B-cell lymphomas; the study includes Diffuse …

• CLINICAL_TRIALS withdrawal · 2026-01-30
  Clinical Trial Update: Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

  A Phase 2 trial evaluating Rituximab, Venetoclax, and Bortezomib for relapsed or refractory diffuse large B-cell lymphoma has been withdrawn…

• CLINICAL_TRIALS trial_result · 2025-09-29
  Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma [Phase 2]

  A Phase 2 clinical trial update notes Polatuzumab Vedotin in combination chemotherapy for previously untreated diffuse large B-cell lymphoma…

• CLINICAL_TRIALS research · 2024-07-22
  Clinical Trial Update: Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL [Phase 2]

  Phase 2 clinical trial evaluating salvage therapy that includes epcoritamab (Epcor) followed by autologous stem cell transplant and epcorita…

• CLINICAL_TRIALS trial_result · 2024-06-11
  Clinical Trial Update: Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]

  Phase 2 trial evaluating Dose Adjusted EPOCH combined with either ofatumumab or rituximab in newly diagnosed or relapsed/refractory Burkitt …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.